Sustained Improvements in Clinical and Patient-Reported Outcomes and Quality of Life Through 5 Years Among Ixekizumab-Treated Patients with Complete Clearance of Scalp Psoriasis by Week 60

By sjmartinez • April 23, 2024

Egeberg A, Hawkes JE, Somani N, Burge R, See K, Gallo G, McKean-Matthews M, Gooderham M, Han G, Armstrong A. Sustained Improvements in Clinical and Patient-Reported Outcomes and Quality of Life Through 5 Years Among Ixekizumab-Treated Patients with Complete Clearance of Scalp Psoriasis by Week 60. Dermatol Ther (Heidelb). 2024 Apr 22. doi: 10.1007/s13555-024-01147-7. Epub ahead of print. PMID: 38647975.

Tags: Clinical outcomes, Dermatology, ixekizumab, long-term, patient-reported outcomes, psoriasis, Publications, Quality of Life, Scalp clearance

UTX coordinates TCF1 and STAT3 to control progenitor CD8+ T cell fate in autoimmune diabetes

Chen HC, Bang MF, Wang HH, Shpargel KB, Kohn LA, Sailer D, Zhang S, McCarthy EC, Seyedsadr M, Stevens S, Pham CLH, Zhou Z, Yin[...]

Dupilumab for bullous pemphigoid: Umbrella review of systematic reviews and meta-analyses

Thapa M, Green B, Kasperkiewicz M. Dupilumab for bullous pemphigoid: Umbrella review of systematic reviews and meta-analyses. JAAD Int. 2025 Oct 18;24:172-176. doi: 10.1016/j.jdin.2025.10.004. PMID:[...]

A novel case of acute localized and generalized exanthematous pustulosis following IL-2 analogue injection amplified by immune checkpoint inhibition

Johnsen NA, Carlisle R, Baghoomian W, Pierce JL, Nguyen MO. A novel case of acute localized and generalized exanthematous pustulosis following IL-2 analogue injection amplified[...]